Abstract:Abstract Acute myeloid leukemia (AML) is a hematologic malignancy characterized by the clonal proliferation of immature blast cells in the peripheral blood and bone marrow. AML is the second most common type of childhood leukemia, and 50% to 60% of relapses occur within the first year of diagnosis. Chemotherapy side effects and resistance are becoming major clinical issues. Although anthracyclines are one of the most commonly used induction regimens for children with AML in the United States, clinicians avoid them due to adverse effects and clinical resistance issues. To address this clinical issue, we are looking for a novel AML approach to boost the usage of anthracyclines. Since Bcl-2 protein overexpression in AML is related to uncontrolled growth, poor prognosis, and chemoresistance. Multiple clinical trials have suggested combining venetoclax (a selective Bcl-2 inhibitor) with well-established medicines to boost efficacy and overcome resistance. We suggest that inhibiting Bcl-2 is a feasible strategy for increasing the use of anthracycline medicines. We proposed combining doxorubicin and venetoclax as an alternative approach for AML patients. In a panel of three AML cell lines, Kusami-1, U937, and THP-1, our western blot revealed that Kusami-1 had the highest expression of Bcl-2 proteins. Surprisingly, venetoclax causes Kusami-1 cell death and increases the efficacy of doxorubicin in a dose-dependent manner, suggesting that utilizing a lower clinical standard dose may avoid major adverse effects such as cardiotoxicity. Furthermore, the Annexin V Apoptosis Detection Kit indicated that venetoclax coupled with doxorubicin synergistically promoted total apoptosis in Kusami-1 cells. The combination medication shown promising and synergistic in vitro anti-leukemic action against AML cell lines and represents a potentially viable treatment option for AML patients. Future research will use the combination approach in AML cell lines, as well as in patient samples and in vivo experiments. Citation Format: Osama Aloudat, Omar S. Al Odat, Tulin Budak-Alpdogan, Subash Jonnalagadda, Yong Chen, Manoj Pandey. Venetoclax triggers apoptosis and augments the effectiveness of doxorubicin against acute myeloid leukemia cells [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 7218.

Apoptosis induced by VX-680 in leukemia cells from AML patients relapsed after allogeneic stem cell transplantation in vitro

Effect of Aurora Inhibitor VX-680 on Proliferation and Apoptosis of CML Cells

Aurora Kinase Inhibitory VX-680 Increases Bax/Bcl-2 Ratio and Induces Apoptosis in Aurora-A-high Acute Myeloid Leukemia.

Inhibition of Mitotic Kinase Aurora Suppresses Akt-1 Activation and Induces Apoptotic Cell Death in All-Trans Retinoid Acid-Resistant Acute Promyelocytic Leukemia Cells

Experimental Study of Apoptosis in Leukemic Cell Lines Induced by Combined Use of Bevacizumab and Chemotherapeutic Drug

Up-Regulation Of Vegf And Its Receptor In Refractory Leukemia Cells

[Effect of Vascular Endothelial Growth Factor on Apoptosis and Expression of Bcl-2 and Mcl-1 in Acute Leukemia Cells].

Aurora kinase small molecule inhibitor destroys mitotic spindle, suppresses cell growth, and induces apoptosis in oral squamous cancer cells.

Combination of RSK Inhibitor LJH-685 and FLT3 Inhibitor FF-10101 Promoted Apoptosis and Proliferation Inhibition of AML Cell Lines

Inhibition of Aurora-A Results in Increased Cell Death in 3-Dimensional Culture Microenvironment, Reduced Migration and is Associated with Enhanced Radiosensitivity in Human Nasopharyngeal Carcinoma

Therapeutic effect of V8 affecting mitophagy and endoplasmic reticulum stress in acute myeloid leukemia mediated by ROS and CHOP signaling

Higher Expression of Cytochrome-c and Caspase-3 in the Primary Acute Lymphoblastic Leukemic Cells with Negative Expression of VEGF and Its Receptors Than with Positive Expressed Cells under VP16 Induction.

Study on effect of vascular endothelial growth factor on acute myeloid leukemic cells in vitro

Vesicular Stomatitis Virus G Glycoprotein and ATRA Enhanced Bystander Killing of Chemoresistant Leukemic Cells by Herpes Simplex Virus Thymidine Kinase/Ganciclovir

Effect of Aurora A inhibitor VX-680 on chemosensitivity in human cervical cancer cell

Sequential intensified conditioning followed by graft-versus-leukemia induction could prevent relapse of refractory acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation

Effect of VEGF on apoptosis and expression of Bcl-2,Mcl-1 and Hsp 90 in HL-60 cell line

α-viniferin induced apoptosis in K562 cells via mitochondrial pathway

Abstract 7218: Venetoclax triggers apoptosis and augments the effectiveness of doxorubicin against acute myeloid leukemia cells

Cotreatment with Vorinostat Enhances Activity of MK-0457 (VX-680) Against Acute and Chronic Myelogenous Leukemia Cells

VX680/MK-0457, a potent and selective Aurora kinase inhibitor, targets both tumor and endothelial cells in clear cell renal cell carcinoma.